Granulomatous inflammation in patients with primary immunodeficiency

Document Type : Review article

Author

department of pediatrics shahid sadoughi university of medical sciences

Abstract

Background and Aim: Granuloma is a delayed type hypersensitivity reaction in response to foreign material. It is manifested by the organized accumulation of mature mononuclear macrophages. Sometimes granuloma may be formed in the absence of external factors. In addition to infectious agents, autoimmune diseases and primary immune deficiencies can cause granuloma. A number of primary immune deficiencies can cause autoimmune disorders and granulomatous inflammation, so these people in addition to frequent infections suffer from non-infectious complications that can have an important effect on prognosis. In this review, we intended to have an overview of primary immunodeficiency diseases with granulomatous inflammation and evaluate the effects of these lesions on the prognosis and course of the disease. Article search was performed by Scopus, Web of Science, and Google Scholar databases. We tried to use the latest and most reliable articles in English and Persian language that are related to our topic. The best articles were selected as references after evaluation of the journal and methodology of the paper.
.
Conclusion: Timely diagnosis and treatment of inflammatory conditions, which sometimes appear before infectious manifestations, will be effective in improving the prognosis of the disease. The treatment of these patients with immunosuppressive drugs and corticosteroids should be based on several factors such as: patient's condition, severity of granulomatous inflammation, and presence of active fungal or bacterial infection.

Keywords

Main Subjects

References

  1. 1. Pagán AJ, Ramakrishnan L. The formation and function of granulomas. Annual review of immunology. 2018;36:639-65.
  2. 2. Williams GT, Williams WJ. Granulomatous inflammation--a review. Journal of clinical pathology. 1983;36(7):723-33.
  3. 3. Co DO, Hogan LH, Il-Kim S, Sandor M. T cell contributions to the different phases of granuloma formation. Immunology letters. 2004;92(1-2):135-42.
  4. 4. Shah KK, Pritt BS, Alexander MP. Histopathologic review of granulomatous inflammation. Journal of clinical tuberculosis and other Mycobacterial Diseases. 2017;7:1-12.
  5. 5. Sacco KA, Gazzin A, Notarangelo LD, Delmonte OM. Granulomatous inflammation in inborn errors of immunity. Frontiers in Pediatrics. 2023;11:1110115.
  6. 6. Yazdani R, Habibi S, Sharifi L, Azizi G, Abolhassani H, Olbrich P, et al. Common Variable Immunodeficiency: Epidemiology, Pathogenesis, Clinical Manifestations, Diagnosis, Classification, and Management. Journal of investigational allergology & clinical immunology. 2020;30(1):14-34.
  7. 7. Aghamohammadi A, Abolhassani H, Latif A, Tabassomi F, Shokuhfar T, Torabi Sagvand B, et al. Long-term evaluation of a historical cohort of Iranian common variable immunodeficiency patients. Expert Review of Clinical Immunology. 2014;10(10):1405-17.
  8. Asgardoon MH, Azizi G, Yazdani R, Sohani M, Pashangzadeh S, Kalantari A, et al. Monogenic primary immunodeficiency disorder associated with common variable immunodeficiency and autoimmunity. International archives of allergy and immunology. 2020;181(9):706-14.
  9. Park JH, Levinson AI. Granulomatous-lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID). Clinical Immunology. 2010;134(2):97-103.
  10. Pashangzadeh S, Delavari S, Shad T, Salami F, Rasouli S, Yazdani R, et al. Non-Infectious Complications in B-Lymphopenic Common Variable Immunodeficiency. Journal of investigational allergology & clinical immunology. 2023:0-.
  11. 11. Mannina A, Chung JH, Swigris JJ, Solomon JJ, Huie TJ, Yunt ZX, et al. Clinical predictors of a diagnosis of common variable immunodeficiency-related granulomatous-lymphocytic interstitial lung disease. Annals of the American Thoracic Society. 2016;13(7):1042-9.
  12. 12. Cinetto F, Scarpa R, Carrabba M, Firinu D, Lougaris V, Buso H, et al. Granulomatous lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID): a multicenter retrospective study of patients from Italian PID referral centers. Frontiers in immunology. 2021;12:627423.
  13. 13. van Stigt AC, Dik WA, Kamphuis LS, Smits BM, van Montfrans JM, van Hagen PM, et al. What works when treating granulomatous disease in genetically undefined CVID? A systematic review. Frontiers in immunology. 2020;11:606389.
  14. 14. Resnick ES, Moshier EL, Godbold JH, Cunningham-Rundles C. Morbidity and mortality in common variable immune deficiency over 4 decades. Blood, The Journal of the American Society of Hematology. 2012;119(7):1650-7.
  15. 15. Abyazi ML, Bell KA, Gyimesi G, Baker TS, Byun M, Ko HM, et al. Convergence of cytokine dysregulation and antibody deficiency in common variable immunodeficiency with inflammatory complications. Journal of Allergy and Clinical Immunology. 2022;149(1):315-26. e9.
  16. 16. Lamers OA, Smits BM, Leavis HL, de Bree GJ, Cunningham-Rundles C, Dalm VA, et al. Treatment strategies for GLILD in common variable immunodeficiency: a systematic review. Frontiers in immunology. 2021;12:606099.
  17. Fleisher TA, Levinson AI. Autoimmunity in Primary Immunodeficiency Disorders. The Autoimmune Diseases: Elsevier; 2014. p. 403-18.
  18. 18. Poto R, Pecoraro A, Ferrara AL, Punziano A, Lagnese G, Messuri C, et al. Cytokine dysregulation despite immunoglobulin replacement therapy in common variable immunodeficiency (CVID). Frontiers in immunology. 2023;14.
  19. 19. Hajjar J, Voigt A, Conner M, Swennes A, Fowler S, Calarge C, et al. Common variable immunodeficiency patient fecal microbiota transplant recapitulates gut dysbiosis. 2023.
  20. 20. Varricchi G, Poto R, Ianiro G, Punziano A, Marone G, Gasbarrini A, et al. Gut microbiome and common variable immunodeficiency: Few certainties and many outstanding questions. Frontiers in immunology. 2021;12:712915.
  21. Boursiquot J-N, Gérard L, Malphettes M, Fieschi C, Galicier L, Boutboul D, et al. Granulomatous disease in CVID: retrospective analysis of clinical characteristics and treatment efficacy in a cohort of 59 patients. Journal of clinical immunology. 2013;33:84-95.
  22. 22. Najem CE, Springer J, Prayson R, Culver DA, Fernandez J, Tavee J, et al., editors. Intra cranial granulomatous disease in common variable immunodeficiency: case series and review of the literature. Seminars in Arthritis and Rheumatism; 2018: Elsevier.
  23. 23. Aranda CS, Guimarães RR, de Gouveia-Pereira Pimentel M. Combined immunodeficiencies. Jornal de pediatria. 2021;97 Suppl 1(Suppl 1):S39-s48.
  24. 24. Abolhassani H, Chou J, Bainter W, Platt CD, Tavassoli M, Momen T, et al. Clinical, immunologic, and genetic spectrum of 696 patients with combined immunodeficiency. Journal of Allergy and Clinical Immunology. 2018;141(4):1450-8.
  25. 25. Liu H, Yang H, Xu H, Liu J, Tang X, Li H, et New clinical aspects of immune dysregulation in atypical severe combined immunodeficiency due to mutations in IL2RG and RAG1. 2022.
  26. 26. Sharapova SO, Migas A, Guryanova I, Aleshkevich S, Kletski S, Durandy A, et al. Late-onset combined immune deficiency associated to skin granuloma due to heterozygous compound mutations in RAG1 gene in a 14 years old male. Human Immunology. 2013;74(1):18-22.
  27. 27. Van Horn SA, Johnson KM, Childs JM. Rheumatoid-nodule-like cutaneous granuloma associated with recombinase activating gene 1-deficient severe combined immunodeficiency: A rare case. Journal of cutaneous pathology. 2018;45(12):940-3.
  28. 28. De Ravin SS, Cowen EW, Zarember KA, Whiting-Theobald NL, Kuhns DB, Sandler NG, et al. Hypomorphic Rag mutations can cause destructive midline granulomatous disease. Blood. 2010;116(8):1263-71.
  29. 29. Schuetz C, Huck K, Gudowius S, Megahed M, Feyen O, Hubner B, et al. An immunodeficiency disease with RAG mutations and granulomas. New England Journal of Medicine. 2008;358(19):2030-8.
  30. 30. Scarselli A, Di Cesare S, Di Matteo G, De Matteis A, Ariganello P, Romiti ML, et al. Combined immunodeficiency due to JAK3 mutation in a child presenting with skin granuloma. The Journal of allergy and clinical immunology. 2016;137(3):948-51.e5.
  31. 31. Leclerc-Mercier S, Moshous D, Neven B, Mahlaoui N, Martin L, Pellier I, et al. Cutaneous granulomas with primary immunodeficiency in children: a report of 17 new patients and a review of the literature. Journal of the European Academy of Dermatology and Venereology : JEADV. 2019;33(7):1412-20.
  32. 32. Gregoriou S, Trimis G, Charissi C, Kalogeromitros D, Stefanaki K, Rigopoulos D. Cutaneous granulomas with predominantly CD8+ lymphocytic infiltrate in a child with severe combined immunodeficiency. Journal of cutaneous medicine and surgery. 2008;12(5):246-8.
  33. 33. Zhang S, Schlott B, Görlach M, Grosse F. DNA‐dependent protein kinase (DNA‐PK) phosphorylates nuclear DNA helicase II/RNA helicase A and hnRNP proteins in an RNA‐dependent manner. Nucleic acids research. 2004;32(1):1-10.
  34. 34. Mathieu A-L, Verronese E, Rice GI, Fouyssac F, Bertrand Y, Picard C, et al. PRKDC mutations associated with immunodeficiency, granuloma, and autoimmune regulator–dependent autoimmunity. Journal of Allergy and Clinical Immunology. 2015;135(6):1578-88. e5.
  35. 35. Woodbine L, Neal JA, Sasi N-K, Shimada M, Deem K, Coleman H, et al. PRKDC mutations in a SCID patient with profound neurological abnormalities. The Journal of clinical investigation. 2013;123(7):2969-80.
  36. 36. Esenboga S, Akal C, Karaatmaca B, Erman B, Dogan S, Orhan D, et al. Two siblings with PRKDC defect who presented with cutaneous granulomas and review of the literature. Clinical Immunology. 2018;197:1-5.
  37. 37. Woelke S, Valesky E, Bakhtiar S, Pommerening H, Pfeffermann L, Schubert R, et al. Treatment of granulomas in patients with ataxia telangiectasia. Frontiers in immunology. 2018;9:2000.
  38. 38. Khalili A. A Review of Primary Immunodeficiency Diseases with Skin Manifestations. SSU_Journals. 2022;29(10):4164-79.
  39. 39. Rothblum-Oviatt C, Wright J, Lefton-Greif MA, McGrath-Morrow SA, Crawford TO, Lederman HM. Ataxia telangiectasia: a review. Orphanet journal of rare diseases. 2016;11(1):1-21.
  40. 40. Chiam L, Verhagen M, Haraldsson A, Wulffraat N, Driessen G-J, Netea M, et al. Cutaneous granulomas in ataxia telangiectasia and other primary immunodeficiencies: reflection of inappropriate immune regulation? Dermatology. 2011;223(1):13-9.
  41. Amirifar P, Ranjouri MR, Yazdani R, Abolhassani H, Aghamohammadi A. Ataxia‐telangiectasia: A review of clinical features and molecular pathology. Pediatric Allergy and Immunology. 2019;30(3):277-88.
  42. 42. Szczawińska-Popłonyk A, Ossowska L, Jończyk-Potoczna K. Granulomatous Liver Disease in Ataxia-Telangiectasia With the Hyper-IgM Phenotype: A Case Report. Front Pediatr. 2020;8:570330.
  43. 43. Law‐Ping‐Man S, Toutain F, Rieux‐Laucat F, Picard C, Kammerer‐Jacquet S, Magérus‐Chatinet A, et al. Chronic granulomatous skin lesions leading to a diagnosis of TAP 1 deficiency syndrome. Pediatric dermatology. 2018;35(6):e375-e7.
  44. 44. Konstantinou P, Kanariou M, Giliani SC, Pantelidaki A, Kokolakis A, Tosca A. Transporter associated with antigen processing deficiency syndrome: case report of an adolescent with chronic perforated granulomatous skin lesions due to TAP 2 Pediatric dermatology. 2013;30(6):e223-e5.
  45. 45. Villa‐Forte A, de la Salle H, Fricker D, Hentges F, Zimmer J. HLA class I deficiency syndrome mimicking Wegener's granulomatosis. Arthritis & Rheumatism: Official Journal of the American College of 2008;58(8):2579-82.
  46. 46. Zimmer J, Andres E, Donato L, Hanau D, Hentges F, De La Salle H. Clinical and immunological aspects of HLA class I deficiency. Qjm. 2005;98(10):719-27.
  47. 47. Vakkilainen S, Taskinen M, Mäkitie O. Immunodeficiency in cartilage-hair hypoplasia: Pathogenesis, clinical course and management. Scand J Immunol. 2020;92(4):e12913.
  48. 48. Notarangelo LD, Roifman CM, Giliani S. Cartilage-hair hypoplasia: molecular basis and heterogeneity of the immunological phenotype. Current opinion in allergy and clinical immunology. 2008;8(6):534-9.
  49. 49. Moshous D, Meyts I, Fraitag S, Janssen CE, Debré M, Suarez F, et al. Granulomatous inflammation in cartilage-hair hypoplasia: risks and benefits of anti-TNF-α mAbs. The Journal of allergy and clinical immunology. 2011;128(4):847-53.
  50. 50. Crahes M, Saugier-Veber P, Patrier S, Aziz M, Pirot N, Brasseur-Daudruy M, et al. Foetal presentation of cartilage hair hypoplasia with extensive granulomatous inflammation. European journal of medical genetics. 2013;56(7):365-70.
  51. 51. McCann LJ, McPartland J, Barge D, Strain L, Bourn D, Calonje E, et al. Phenotypic variations of cartilage hair hypoplasia: granulomatous skin inflammation and severe T cell immunodeficiency as initial clinical presentation in otherwise well child with short stature. J Clin Immunol. 2014;34(1):42-8.
  52. 52. Yu HH, Yang YH. Chronic Granulomatous Disease: a Comprehensive Review. 2021;61(2):101-13.
  53. 53. Justiz-Vaillant AA, Williams-Persad AF. Chronic Granulomatous Disease (CGD): Commonly Associated Pathogens, Diagnosis and Treatment. 2023;11(9).
  54. 54. Rezaei N, Ghaffari J, Khalili A, Dabbaghzadeh A, Ghaffari N, Abolhassani H, et al. Congenital defects of phagocytes. Inborn Errors of Immunity: Elsevier; 2021. p. 155-217.
  55. Marciano BE, Rosenzweig SD, Kleiner DE, Anderson VL, Darnell DN, Anaya-O'Brien S, et al. Gastrointestinal involvement in chronic granulomatous disease. Pediatrics. 2004;114(2):462-8.
  56. 56. Yu JE, Azar AE, Chong HJ, Jongco AM, 3rd, Prince BT. Considerations in the Diagnosis of Chronic Granulomatous Disease. Journal of the Pediatric Infectious Diseases Society. 2018;7(suppl_1):S6-s11.
  57. 57. Rieber N, Hector A, Kuijpers T, Roos D, Hartl D. Current concepts of hyperinflammation in chronic granulomatous disease. Journal of Immunology Research. 2012;2012.
  58. 58. Kobayashi SD, Voyich JM, Braughton KR, Whitney AR, Nauseef WM, Malech HL, et al. Gene expression profiling provides insight into the pathophysiology of chronic granulomatous disease. The Journal of Immunology. 2004;172(1):636-4
  59. 59. Bylund J, MacDonald KL, Brown KL, Mydel P, Collins LV, Hancock RE, et al. Enhanced inflammatory responses of chronic granulomatous disease leukocytes involve ROS‐independent activation of NF‐κ European journal of immunology. 2007;37(4):1087-96.
  60. 60. Towbin AJ, Chaves I. Chronic granulomatous disease. Pediatric radiology. 2010;40(5):657-68; quiz 792-3.
  61. 61. Winkelstein JA, Marino MC, Johnston Jr RB, Boyle J, Curnutte J, Gallin JI, et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine. 2000;79(3):155-69.
  62. 62. Kis É, Verebély T, Mészner Z. Inflammatory pseudotumor of the bladder in chronic granulomatous disease. Pediatric Nephrology. 2002;17:220-1.
  63. 63. Chiriaco M, Salfa I, Di Matteo G, Rossi P, Finocchi A. Chronic granulomatous disease: Clinical, molecular, and therapeutic aspects. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology. 2016;27(3):242-53.
  64. 64. Seger R. Chronic granulomatous disease: recent advances in pathophysiology and treatment. Neth J Med. 2010;68(11):334-40.
  65. 65. Justiz-Vaillant AA, Williams-Persad AF-A, Arozarena-Fundora R, Gopaul D, Soodeen S, Asin-Milan O, et al. Chronic Granulomatous Disease (CGD): Commonly Associated Pathogens, Diagnosis and Treatment. Microorganisms. 2023;11(9):2233.
Medical Journal of Mashhad university of Medical Sciences
Volume 67, Issue 4
May and June 2024
Pages 1262-1274

Files

Share

How to cite

Statistics